El-Agamawi, A., El-Shishtawy, W., Al-Sharif, A. (2018). Tamoxifen versus Tamoxifen and Ovarian Suppression in Premenopausal Hormone Positive early Breast Cancer (Retrospective study). The Egyptian Journal of Hospital Medicine, 73(10), 7720-7725. doi: 10.21608/ejhm.2018.19996
Ahmed Yosry El-Agamawi; Wael Helmy El-Shishtawy; Ashraf Ibrahim Basiony Ali Al-Sharif. "Tamoxifen versus Tamoxifen and Ovarian Suppression in Premenopausal Hormone Positive early Breast Cancer (Retrospective study)". The Egyptian Journal of Hospital Medicine, 73, 10, 2018, 7720-7725. doi: 10.21608/ejhm.2018.19996
El-Agamawi, A., El-Shishtawy, W., Al-Sharif, A. (2018). 'Tamoxifen versus Tamoxifen and Ovarian Suppression in Premenopausal Hormone Positive early Breast Cancer (Retrospective study)', The Egyptian Journal of Hospital Medicine, 73(10), pp. 7720-7725. doi: 10.21608/ejhm.2018.19996
El-Agamawi, A., El-Shishtawy, W., Al-Sharif, A. Tamoxifen versus Tamoxifen and Ovarian Suppression in Premenopausal Hormone Positive early Breast Cancer (Retrospective study). The Egyptian Journal of Hospital Medicine, 2018; 73(10): 7720-7725. doi: 10.21608/ejhm.2018.19996
Tamoxifen versus Tamoxifen and Ovarian Suppression in Premenopausal Hormone Positive early Breast Cancer (Retrospective study)
Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Al-Azhar University
Abstract
Background: breast cancer is the most frequently diagnosed cancer globally and is the leading cause of cancer-related death in women. The American Cancer Society estimated that 249, 260 Americans were diagnosed with invasive breast cancer and 40, 890 were died of the disease in the United States in 2016.Aim of the Work: this was a retrospective study aimed to evaluate the disease free survival, overall survival and toxicity profile in premenopausal breast cancer patient who received tamoxifen versus tamoxifen with ovarian suppression (LHRH) agonists as adjuvant hormonal treatment.Patients and Methods: this was a retrospective cohort study. Premenopausal Female patients with Breast Cancer, who received Tamoxifen with or without Ovarian Function Suppression (LHRH agonist for 2 years) as adjuvant hormonal treatment, presented to clinical Oncology Department, Al-Hussein University Hospital in the period between January 2008 and January 2015 in Breast Cancer Unit, Clinical Oncology Department, Al-Hussein University Hospital. Results: in our retrospective analysis there was no statistical significant difference in the primary endpoint of DFS between group I who received tamoxifen and group II receiving tamoxifen plus ovarian suppression (2-year DFS, 65.3% vs. 75.0%) with (P value=0.838 not significant).Conclusion: we concluded that adding ovarian suppression to tamoxifen did not provide a significant benefit in the overall population of premenopausal women in this study (P=0.15 not significant).
View on SCiNiTO
Top